Eutilex logo

Eutilex Co., Ltd.

Eutilex is a clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”263050.KQ” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.eutilex.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODEKOSDAQ: 263050
Address
Suite# 1401 Daeryung Technotown 17 Gasan digital 1-ro 25, Geumcheon-gu, 8594
Seoul
South Korea
Email
Contact Number
+82 2 3402 7310

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Dec 2016, Eutilex raised $21 billion KRW (US $18.9M) in Series A financing led by DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. This new funding brings the total capital raised by Eutilex to 30.5 billion KRW (US $27.7M) since its founding in 2015.